NLR ≤ 4.3

NLR > 4.3

significance

n

%

n

%

Gender

male

23

59.0

21

47.7

ns

female

16

41.0

23

52.3

Age

< 45 years

20

51.3

26

59.1

ns

≥ 45 years

19

48.7

18

40.9

Hemoglobin level

> 10.5 g/dl

29

74.4

33

75.0

ns

< 10.5 g/dl

10

25.6

11

25.0

White blood cell count

< 15,000/µl

36

92.3

36

81.8

ns

≥ 15,000/µl

3

7.7

8

18.2

Lymphocyte count

< 600/µl or < 8%

3

7.7

11

25.0

0.036^*

≥ 600/µl or ≥ 8% ne

36

92.3

33

75.0

Elevated LDH

no

27

69.2

31

70.5

ns

yes

12

30.8

13

29.5

B symptoms

no

20

52.6

17

40.5

ns

yes

18

47.4

25

59.5

PH

subtype

MC

4

10.3

3

6.8

ns

NS

17

43.6

10

22.7

LD

3

7.7

1

2.3

LP

3

7.7

3

6.8

NS/MC

12

30.8

27

61.4

Clinical

stage

I

1

2.6

2

4.5

ns

II

23

59.0

19

43.2

III

9

23.1

11

25.0

IV

6

15.4

12

27.3

ECOG

0

23

60.5

19

45.2

ns

1

9

23.7

12

28.6

2

3

7.9

5

11.9

3

3

7.9

4

9.5

4

0

0.0

2

4.8

IPS

< 4

32

82.1

33

75.0

ns

≥ 4

7

17.9

11

25.0

Bulky

disease

no

29

74.4

28

63.6

ns

yes

10

25.6

16

36.4

Extranodal

disease

no

34

87.2

37

84.1

ns

yes

5

12.8

7

15.9

GHSG

early favorable

10

25.6

6

13.6

ns

early unfavorable

13

33.3

15

34.1

advanced

16

41.0

23

52.3

EORTC

early favorable

8

20.5

5

11.4

ns

early unfavorable

16

41.0

14

31.8

advanced

15

38.5

25

56.8

Response to treatment (N = 79)

CR

30

85.7

33

75.0

ns

PR, SD, progression

5

14.3

11

25.0

Treatment outcome

dead

8

20.5

21

48.8

0.007^**

alive

31

79.5

22

51.2

lost in follow up

0

0.0

1

2.3